Disease Activity During Pregnancy and Postpartum in Women With Multiple Sclerosis Treated With Ocrelizumab or Rituximab Before Pregnancy. (PubMed, Neurol Neuroimmunol Neuroinflamm) - Oct 10, 2026 - "Relapses and disability during and after pregnancy after OCR/RTX interruption are rare and independent of timing and number of cycles. However, potential differences may not be detectable due to the low number of events and should be evaluated in larger studies. In addition, the applicability to ofatumumab, given its different dosing interval, remains unclear."
Journal • CNS Disorders • Multiple Sclerosis
|
|
Karen Dost-Kovalsky; Kerstin Hellwig; Laura Witt; Nadine Bast; Ralf Gold; Sabrina Haben; Sandra Thiel
|